FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation 
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Asia Stocks Pause as Tech Earnings, Fed Signals, and Dollar Weakness Drive Markets 
Philippine Economy Slows in Late 2025, Raising Expectations of Further Rate Cuts 
South Korea Industry Minister Heads to Washington Amid U.S. Tariff Hike Concerns 
Indonesia Stocks Face Fragile Sentiment After MSCI Warning and Market Rout 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Researchers from the Korea Advanced Institute of Science and Technology (KAIST) have developed a wearable green organic light-emitting diode (OLED) with a 470-nanometer (nm) wavelength that can cure jaundice in infants.
The OLED provides sufficient power for jaundice treatment even at low voltage, durability for over 100 hours of operation, a low operating temperature of less than 35 Celsius degrees, and flexibility that can endure over 1,000 bends at a 2 mm radius of curvature.
The bilirubin level of the infants’ serum reaches 12 milligrams per decilitre (mg/dL) within three hours of being exposed to the OLED, indicating the completed treatment of jaundice.
Unlike existing light-emitting diode (LED)-based jaundice treatment devices currently used at hospitals, the OLED showed uniform and effective treatment functions.
